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ABSTRACT
Objectives: The human papillomavirus (HPV)
immunisation programme in England was introduced
in 2008. Monitoring changes in type-specific HPV
prevalence allows assessment of the population impact
of this vaccination programme.
Methods: Residual vulva-vaginal swab specimens
were collected from young sexually active women (aged
16–24 years) attending for chlamydia screening across
England. Specimens were collected between 2010 and
2013 for type-specific HPV-DNA testing. HPV
prevalence was compared to a similar survey conducted
in 2008 prior to the introduction of HPV vaccination.
Results: A total of 7321 specimens collected in the
postvaccination period, and 2354 specimens from the
prevaccination period were included in this analysis.
Among the individuals aged 16–18 years, with an
estimated vaccination coverage of 67%, the prevalence
of HPV16/18 infection decreased from 17.6% in 2008
to 6.1% in the postvaccination period. Within the
postvaccination period, there was a trend towards lower
HPV16/18 prevalence with higher vaccination coverage
and increasing time since vaccine introduction from
8.5% in the period 2–3 years postvaccination to 4.0% in
the period 4–5 years postvaccination. The prevalence of
HPV31 reduced from 3.7% in the prevaccination period
to 0.9% after vaccine introduction, although this no
longer reached statistical significance after additional
consideration of the uncertainty due to the assay
change. Smaller reductions were seen in the individuals
aged 19–21 years with lower estimated vaccination
coverage, but there was no evidence of a reduction in
the older unvaccinated women. Some overall increase in
non-vaccine types was seen in the youngest age groups
(ORs (95% CI); 1.3 (1.0 to 1.7) and 1.5 (1.1 to 2.0) for
individuals aged 16–18 and 19–21 years, respectively,
when adjusted for known population changes and the
change in assay) although this should be interpreted
with caution given the potential unmasking effect.
Conclusions: These data demonstrate a reduction in
the HPV vaccine types in the age group with the highest
HPV vaccination coverage.
INTRODUCTION
Persistent infection with a high-risk (HR)
human papillomavirus (HPV) type is a neces-
sary cause of cervical cancer, and has been
shown to be associated with other cancers in
men and women.1 2 Two of these HR-HPV
types, HPV16 and HPV18, are present in
around 70–80% of cervical cancers.3 4
Infection with low-risk (LR) HPV6 or HPV11
has been shown to be associated with the vast
majority of genital warts.5
HPV vaccination of young females has
been introduced widely in developed coun-
tries as well as in some developing countries6
since 2007, using the ﬁrst two licensed vac-
cines (a bivalent HPV16/18 vaccine and
quadrivalent HPV6/11/16/18 vaccine).
In late 2008, the UK began providing HPV
vaccination, free at the point of delivery,
routinely to 12-year-old females, and
catch-up vaccination to females up to and
including 17-year-olds. The bivalent vaccine
was offered until September 2012 when the
programme changed to offer the quadriva-
lent vaccine. Throughout the UK, over 80%
of females eligible for routine vaccination
each year have completed the three-dose
course.7–9 Three-dose coverage within the
Strengths and limitations of this study
▪ We conducted human papillomavirus (HPV) sur-
veillance among a large number of young
women attending for chlamydia screening, with
HPV type-specific testing performed for almost
10,000 women.
▪ The large sample size of this study has allowed
us to consider the population impact of the
bivalent HPV vaccine against the two vaccine
types, and against cross-protective HPV types.
▪ We demonstrate continued decreases in the
prevalence of vaccine-targeted HPV types over
time up to 4 years after the introduction of the
bivalent vaccination programme.
▪ Analyses compare data from repeat cross-
sectional surveys. Therefore, unrecorded
changes in the population characteristics may
have resulted in a change in HPV prevalence
which is unrelated to HPV vaccination.
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catch-up ages has been lower, with average coverage of
73% for individuals aged 14–15 years, and 45% for 16–
17 years,7 although this is still higher than in most other
countries.10–12
In 2013, we reported ﬁndings from our surveillance of
type-speciﬁc HPV infections in sexually active young
females in England, showing evidence of substantially
lower HPV16/18 prevalence in the ﬁrst 4000 postvacci-
nation period specimens tested compared with prevacci-
nation prevalence.13 Reductions in the prevalence of
HPV16/18 following the introduction of HPV vaccin-
ation have also been shown in Australia,14 the USA,15–17
Scotland18 and Sweden.19
Some cross-protection against non-vaccine HR-HPV
types closely related to HPV16/18 has been demon-
strated in clinical trials of both vaccines (speciﬁcally,
HPV31, HPV33 and HPV45 for the bivalent vaccine, and
HPV31 for the quadrivalent vaccine),20–22 and has been
observed for the bivalent vaccine by ongoing surveil-
lance of young women undergoing cervical screening in
Scotland.18 Ongoing surveillance for changes in the
prevalence of other non-vaccine HPV types is also
prudent. These changes could result from vaccination
due to cross-protection against non-vaccine HR-HPV
types (ie, causing decreases in prevalence) or due to
type replacement (ie, causing increases in prevalence).
We report further ﬁndings from our ongoing HPV sur-
veillance (now over 7000 postvaccination specimens) in
our high-coverage population, including changes in
vaccine and non-vaccine types. We aimed to determine
to what extent any such observed changes were likely to
have resulted from vaccination, rather than be due to
methodological reasons (eg, assay performance,
unmasking), or a result of other factors such as changes
in sexual behaviour over time.
METHODS
The methods of specimen selection, collection and
testing, and the characteristics of the study population
have been described previously.13 23 Brieﬂy, residual
vulva-vaginal swab specimens were collected via 10
laboratories from young women aged 16–24 years under-
going chlamydia screening at general practice, commu-
nity and sexual health services (CaSH, otherwise known
as family planning), and youth clinics. Residual speci-
mens were all sent for HPV testing at the Virus
Reference Department laboratory at Public Health
England (PHE). In England, chlamydia screening is
recommended for all sexually active men and women
under 25 years old annually, and on partner change,
irrespective of symptoms or perceived risk. Demographic
data were reported separately and linked to the speci-
mens received at the PHE Centre for Infectious Disease
Surveillance and Control. Prior to testing for HPV DNA,
specimens were unlinked from any patient-identiﬁable
data and anonymised. This study was reviewed and
approved by the South East Research Ethics Committee
(REC reference: 10/H1102/7). Individual patient
consent was not required as this study tested anonymised
specimens (with no patient-identiﬁable data) as part of
Public Health Surveillance conducted to monitor the
HPV vaccination programme.
Prevaccination-period specimens were collected
between January and September 2008, prior to the intro-
duction of the national HPV vaccination programme
in England. Postvaccination-period specimens were
collected between October 2010 and April 2013, and
divided into two periods, 2–3 (ie, 2010–2011) and
4–5 years (ie, 2012–2013) postvaccination.
Postvaccination specimens were tested for type-speciﬁc
HPV DNA to detect 13 HR types (HPV16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59 and 68), ﬁve possible HR types
(HPV26, 53, 70, 73 and 82) and two LR types (HPV6
and 11) using an in-house multiplex PCR and
Luminex-based genotyping test with pyruvate dehydro-
genase (PDH) detection for sample integrity.24
Prevaccination specimens were tested by Hybrid Capture
2 (HC2) HPV DNA test using the Combined Probe
Cocktail Method to detect HR and possible HR types (as
above) and ﬁve LR types (6, 11, 42, 43 and 44) and gen-
otyped by the Linear Array HPV Genotyping (LA) test
(Roche Molecular Systems) if HC2 positive.
HPV prevalence was calculated for each individual
HPV type. We also calculated combined HPV preva-
lence, restricted to types included in the prevaccination
and postvaccination assays, for (1) any HR-HPV type; (2)
the HR-HPV types included in the current vaccines:
HPV16 and/or 18; (3) the additional HR-HPV types
included in the nonavalent HPV vaccine25: HPV31, 33,
45, 52 and/or 58; (4) the HPV types for which there is
some evidence of cross-protection from clinical trials:
HPV31, 33 and/or 45 and (5) the non-vaccine HR-HPV
types (ie, HR types not including HPV16 or 18).
Changes in prevalence between the prevaccination and
postvaccination (combined) periods were compared
using ORs calculated using a logistic regression model.
Trends over time were assessed by including three time
periods (prevaccination, 2–3 years postvaccination,
4–5 years postvaccination) as an ordered continuous
variable. Adjusted ORs were calculated adjusting for age,
testing venue type and chlamydia positivity (as a marker
for sexual behaviour). To account for the change in
assay between the prevaccination and postvaccination
periods, we used type-speciﬁc sensitivity and speciﬁcity
estimates from a validation study (428 prevaccination
specimens, retested through the postvaccination testing
system13). The logitem command in Stata was used to
adjust for the different sensitivity and speciﬁcity of the
assay used in the prevaccination period. This command
performs logistic regression when the binary outcome is
measured with uncertainty. This adjustment did not
account for the uncertainty surrounding the sensitivity
and speciﬁcity estimates, hence, bootstrapping techni-
ques were used to incorporate this additional uncer-
tainty to the SEs of the ORs. A similar statistical model
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to adjust for assay change was not available for use with
prevalence ratios (PR). However, PRs adjusted for age,
testing venue type, and chlamydia positivity were also
calculated using a log binomial model and the results
compared with the equivalent ORs.
In order to further address concerns about changes in
prevalence of HPV in the postvaccination period unre-
lated to vaccine introduction (eg, changes in sexual
behaviour not addressed by adjustment of chlamydia
positivity or residual changes in assay sensitivity), we also
compared prevaccination and postvaccination type-
speciﬁc prevalence when restricted to specimens with at
least one HR-HPV type detected. This enabled assess-
ment of changes in the relative, rather than absolute,
frequency of speciﬁc HR types. To give a simple
example, if prevaccination specimens comprised 20%
HR type positivity overall (10% prevalence of type 31
and 10% prevalence of type 33), and postvaccination
specimens comprised 30% HR type positivity (15%
prevalence of type 31 and 15% prevalence of type 33),
the absolute frequency of each type would increase post-
vaccination. However, the relative prevalence of each
type within the HR-HPVs positives would remain the
same.
Vaccination coverage by age and time period was
derived from published data.7–9 26
RESULTS
Demographics and characteristics
Results were analysed from 2354 prevaccination speci-
mens and 7321 postvaccination specimens: 3602
(49.2%) from 2–3 years postvaccination, and 3719
(50.8%) from 4–5 years postvaccination. The character-
istics of study participants were similar in the prevaccina-
tion and postvaccination periods (table 1), except there
were more specimens from women of non-white ethnic
groups, and fewer specimens collected from youth
clinics in the postvaccination collection (7.3% vs 17.6%,
and 24.1% vs 3.1%, respectively). Furthermore, two
laboratories, Leeds and Lewisham, included in only the
postvaccination period, had notably higher chlamydia
positivity rates than the other laboratories (22.4% and
8.4%, respectively). Data from these laboratories were
excluded in sensitivity analyses. In the postvaccination
period, the estimated vaccination coverage in the surveil-
lance population, based on nationally reported data, was
67.2%, 30.7% and 0.6% for individuals aged 16–18, 19–
21 and 22–24 years, respectively (table 2 for estimates by
time period).
HR HPV16 and/or 18 infection
In the youngest age group (16–18 years), the prevalence
of HPV16/18 was 17.6% in the prevaccination period
compared to 8.5% in the period 2–3 years postvaccina-
tion, and 4.0% 4–5 years postvaccination (p value for
trend <0.001; table 2 and ﬁgure 1). This corresponds to
an overall reduction of 66% comparing the
prevaccination prevalence to the combined postvaccina-
tion prevalence. A trend was also seen in individuals
aged 19–21 years with a prevaccination prevalence of
16.9% compared to 14.2% in the period 2–3 years post-
vaccination, and 8.7% 4–5 years postvaccination (p value
for trend <0.001; combined reduction between the pre-
vaccination and postvaccination periods of 31%).
However, there was no decrease in the prevalence of
HPV16 and/or HPV18 in the oldest age group, who
were largely unvaccinated. There was a slight decrease in
HPV18 infection in the oldest age group, but this differ-
ence was no longer seen once adjustment was made for
changes in population and HPV assay (data not shown).
The adjusted ORs for the postvaccination periods
(combined) compared with the prevaccination period
were 0.3 (95% CI 0.2 to 0.4), 0.6 (95% CI 0.5 to 0.9)
and 1.1 (95% CI 0.8 to 1.7) for individuals aged 16–18,
19–21 and 22–24 years, respectively (table 3).
HR HPV31, 33 and/or 45 infection (cross-protective
HPV types)
The prevalence of HPV31, 33 and/or 45 among the
individuals aged 16–18 years was 8.4% in the prevaccina-
tion period, 6.9% in the period 2–3 years postvaccina-
tion, and 5.8% 4–5 years postvaccination. After adjusting
for demographics and the change in HPV assay, the
adjusted OR postvaccination (combined) was 0.9 (95%
CI 0.5 to 1.5), p value=0.58 (tables 2 and 3). The preva-
lence of HPV31 in this age group reduced from 3.7% in
the prevaccination period to 0.9% in the combined post-
vaccination period. This reduction did not reach statis-
tical signiﬁcance after adjustment for the known
population changes and the assay change (adjusted OR
0.4 (95% CI 0.2 to 2.9), p value=0.21): there was no evi-
dence of a reduction in the overall prevalence of HPV33
or of HPV45. Among women aged 16–18 years with at
least one non-vaccine HR-HPV type detected, the preva-
lence of HPV31/33/45 was 48% lower in the period 4–
5 years postvaccination compared to the prevaccination
period, with a reduction from 14.9% to 3.7% for
HPV31, 9.6% to 7.9% for HPV33, and 11.5% to 6.5%
for HPV45 (see online supplementary table S1). In the
older age groups, with lower vaccination coverage, there
was no evidence of a reduction in these three HPV types
between the prevaccination and postvaccination periods.
Non-vaccine HR-HPV types
There was an increase in the prevalence of non-vaccine
HR-HPV types between the prevaccination and postvacci-
nation periods at all ages (24.9–33.7%, 26.9–39.6% and
26.4–32.9% for individuals aged 16–18, 19–21 and 22–
24 years, respectively). After adjustment for age, venue
type, chlamydia positivity and the change in assay, the
adjusted ORs comparing the prevaccination and postvac-
cination prevalence were 1.3 (1.0 to 1.7), 1.5 (1.1 to 2.0)
and 1.2 (0.9 to 1.6) for individuals aged 16–18, 19–21
and 22–24 years, respectively (table 3). There was also
evidence for increases in the prevalence of the
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additional nonavalent HR-HPV types in the age group of
19–21 years. Adjusted ORs were 1.2 (0.9 to 1.7), 1.5 (1.1
to 2.2) and 1.3 (0.9 to 2.0), respectively. This increase in
non-vaccine HR-HPV types was only seen between the
prevaccination and postvaccination combined periods.
Within the postvaccination period, there was no evi-
dence of a change in the prevalence of these HR-HPV
types over time (table 2).
The type-speciﬁc prevalence of HPV58 was similar in
the prevaccination and postvaccination period for all age
groups. However, there was an increase in the prevalence
of HPV52 even after adjustment (adjusted OR 1.7 (1.0 to
3.2) and 2.4 (1.4 to 4.7), respectively) for individuals
aged 16–18 and 19–21 years, and a borderline increase
for individuals aged 22–24 years (1.6 (0.9 to 3.6)).
LR HPV6 and/or 11 infection
Similar to the non-vaccine HR types, there was a signiﬁ-
cant increase in the prevalence of HPV6/11 in the post-
vaccination period among women aged 16–18 years
(5.8% prevaccination vs 8.3% postvaccination; adjusted
OR 1.9 (1.1 to 3.4)). There was also a slight increase in
the LR types for individuals aged 19–21 years (5.8% vs
7.6%, respectively; adjusted OR 1.4 (0.8 to 2.6))
although after adjustment for age, venue type, chla-
mydia positivity and the change in assay, this was not sig-
niﬁcant (p=0.15). There was no evidence of a change in
the prevalence of HPV6/11 in the older age group (22–
24-years, 4.4% prevaccination vs 4.3% postvaccination;
adjusted OR 1.2 (0.6 to 4.1)).
Repeating analyses using PRs instead of ORs (adjusted
for all factors except for assay change) gave very similar
results for all HPV types (results not shown).
DISCUSSION
This surveillance of young sexually active women under-
going chlamydia screening has demonstrated continuing
reductions in the prevalence of the HPV vaccine types
following the introduction of a high-coverage national
Table 1 Characteristics of women included in the prevaccination and postvaccination surveys
Prevaccination
(2008)
Postvaccination
(2010–2011)
Postvaccination
(2012–2013)
(n=2354) (n=3602) (n=3719)
Number of samples by laboratory
North West (Aintree) 472 (20.1%) 170 (4.7%) 350 (9.4%)
Yorkshire and The Humber (Leeds) – 620 (17.2%) 883 (23.7%)
West Midlands (Stoke) 260 (11.0%) 259 (7.2%) 219 (5.9%)
East of England (Norfolk and Norwich) 759 (32.2%) 222 (6.2%) 123 (3.3%)
East of England (Cambridge) – 345 (9.6%) 588 (15.8%)
South East (East Kent) – 563 (15.6%) 935 (25.1%)
South East (Portsmouth) – 81 (2.2%) –
South West (Cornwall) 473 (20.1%) 439 (12.2%) 453 (12.2%)
London (University College London) 390 (16.6%) 476 (13.2%) –
London (Lewisham) – 427 (11.9%) 168 (4.5%)
Age, years (data completeness) (100%) (100%) (100%)
16–18 1047 (44.5%) 933 (25.9%) 1063 (28.6%)
19–21 804 (34.2%) 1463 (40.6%) 1310 (35.2%)
22–24 503 (21.4%) 1206 (33.5%) 1346 (36.2%)
Ethnicity (data completeness) (88%) (76%) (62%)
White 1924 (92.7%) 2119 (77.1%) 2058 (88.6%)
Black 93 (4.5%) 392 (14.3%) 158 (6.8%)
Asian 25 (1.2%) 75 (2.7%) 46 (2.0%)
Other 34 (1.6%) 144 (5.2%) 46 (2.0%)
Sample collection venue (data completeness) (100%) (100%) (100%)
General practice 608 (25.8%) 1085 (30.1%) 1257 (33.8%)
Family planning (Community Sexual Health Services) 1179 (50.1%) 2429 (67.4%) 2320 (62.4%)
Youth clinic 567 (24.1%) 88 (2.4%) 142 (3.8%)
2+ sexual partners in the previous 12 months
(data completeness)
53.6% (81%) 46.6% (45%) 48.6% (31%)
New sexual partner in the previous 3 months
(data completeness)
48.1% (81%) 48.1% (47%) 51.3% (32%)
Chlamydia positivity (data completeness) 8.9% (99%) 7.3% (99.8%) 8.5% (100%)
Chlamydia positivity (excluding Leeds and Lewisham)
(data completeness)
NA 4.7% (99.8%) 2.7% (100%)
Proportion eligible for HPV vaccination 0.0% 45.6% 61.3%
Estimated vaccination coverage 0.0% 24.3% 35.8%
NA, not applicable.
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HPV vaccination programme as well as some evidence of
overall reductions in HPV31 (the closely related HPV
type with strongest evidence of cross-protection from the
bivalent vaccine clinical trials22). Encouragingly, these
reductions are more marked in the later postvaccination
period with higher estimated vaccination coverage. Use
of bootstrapping techniques to account for the uncer-
tainty of the speciﬁcity and sensitivity estimates from the
validation study provided conservative estimates with
wider CIs. Once we accounted for this additional
Table 2 Estimates of prevalence of HPV types by age in prevaccination and postvaccination periods
HPV type
Prevaccination
prevalence (%)
2008
(95% CI)
n=2354
Postvaccination
prevalence (%)
2010–2011
(95% CI)
n=3602
Postvaccination
prevalence (%)
2012–2013
(95% CI)
n=3719
p-value for
trend
16–18 years
(Estimated HPV16/18 vaccination
coverage)
(0%) (60.2%) (73.4%)
Any high-risk HPV 32.6 (29.7 to 35.4) 37.6 (34.5 to 40.7) 35.4 (32.5 to 38.3) 0.188
Any non-vaccine high-risk HPV 24.9 (22.3 to 27.6) 34.2 (31.1 to 37.2) 33.2 (30.4 to 36.0) <0.001
Vaccine HPV types
HPV16 and/or 18 17.6 (15.3 to 19.9) 8.5 (6.7 to 10.3) 4.0 (2.8 to 5.1) <0.001
HPV16 11.9 (10.0 to 13.9) 6.8 (5.1 to 8.4) 3.0 (2.0 to 4.0) <0.001
HPV18 7.8 (6.2 to 9.5) 2.8 (1.7 to 3.8) 1.1 (0.5 to 1.8) <0.001
Nonavalent HPV types*
HPV31/33/45/52/58 14.5 (12.4 to 16.7) 17.7 (15.2 to 20.1) 14.9 (12.7 to 17.0) 0.835
HPV31/33/45 8.4 (6.7 to 10.1) 6.9 (5.2 to 8.5) 5.8 (4.4 to 7.2) 0.021
HPV31 3.7 (2.6 to 4.9) 0.5 (0.1 to 1.0) 1.2 (0.6 to 1.9) <0.001
HPV33 2.4 (1.5 to 3.3) 3.5 (2.3 to 4.7) 2.6 (1.7 to 3.6) 0.739
HPV45 2.9 (1.9 to 3.9) 2.9 (1.8 to 4.0) 2.2 (1.3 to 3.0) 0.314
HPV52 4.0 (2.8 to 5.2) 8.6 (6.8 to 10.4) 6.4 (4.9 to 7.9) 0.027
HPV58 3.7 (2.6 to 4.9) 4.0 (2.7 to 5.2) 3.9 (2.7 to 5.0) 0.875
19–21 years
(Estimated HPV16/18 vaccination
coverage)
(0%) (21.4%) (41.1%)
Any high-risk HPV 34.3 (31.0 to 37.6) 45.9 (43.4 to 48.5) 44.2 (41.5 to 46.9) <0.001
Any non-vaccine high-risk HPV 26.9 (23.8 to 29.9) 39.1 (36.6 to 41.6) 40.2 (37.5 to 42.8) <0.001
Vaccine HPV types
HPV16 and/or 18 16.9 (14.3 to 19.5) 14.2 (12.4 to 16.0) 8.7 (7.2 to 10.2) <0.001
HPV16 12.6 (10.3 to 14.9) 11.1 (9.5 to 12.7) 7.5 (6.1 to 8.9) <0.001
HPV18 6.5 (4.8 to 8.2) 3.8 (2.8 to 4.7) 1.7 (1.0 to 2.4) <0.001
Nonavalent HPV types*
HPV31/33/45/52/58 15.2 (12.7 to 17.7) 21.2 (19.1 to 23.3) 20.2 (18.1 to 22.4) 0.015
HPV31/33/45 8.3 (6.4 to 10.2) 8.7 (7.2 to 10.1) 8.8 (7.2 to 10.3) 0.736
HPV31 4.7 (3.3 to 6.2) 2.3 (1.5 to 3.0) 2.7 (1.8 to 3.5) 0.019
HPV33 2.0 (1.0 to 3.0) 2.9 (2.0 to 3.7) 3.4 (2.4 to 4.4) 0.058
HPV45 2.6 (1.5 to 3.7) 3.7 (2.7 to 4.7) 3.2 (2.3 to 4.2) 0.581
HPV52 4.1 (2.7 to 5.5) 10.0 (8.5 to 11.6) 10.3 (8.7 to 12.0) <0.001
HPV58 5.0 (3.5 to 6.5) 4.6 (3.6 to 5.7) 4.0 (2.9 to 5.0) 0.256
22–24 years
(Estimated HPV16/18 vaccination
coverage)
(0%) (0%) (1.1%)
Any high-risk HPV 32.8 (28.7 to 36.9) 40.4 (37.6 to 43.2) 42.4 (39.8 to 45.1) 0.001
Any non-vaccine high-risk HPV 26.4 (22.6 to 30.3) 32.0 (29.4 to 34.6) 33.7 (31.1 to 36.2) 0.007
Vaccine HPV types
HPV16 and/or 18 15.3 (12.2 to 18.5) 16.5 (14.4 to 18.6) 16.1 (14.2 to 18.1) 0.790
HPV16 10.9 (8.2 to 13.7) 14.7 (12.7 to 16.7) 13.6 (11.8 to 15.4) 0.334
HPV18 5.8 (3.7 to 7.8) 2.7 (1.7 to 3.6) 3.0 (2.1 to 3.9) 0.019
Nonavalent HPV types*
HPV31/33/45/52/58 16.7 (13.4 to 20.0) 18.4 (16.2 to 20.6) 21.1 (18.9 to 23.3) 0.020
HPV31/33/45 8.9 (6.4 to 11.4) 7.9 (6.4 to 9.4) 10.1 (8.5 to 11.7) 0.196
HPV31 3.2 (1.6 to 4.7) 2.5 (1.6 to 3.4) 2.7 (1.9 to 3.6) 0.770
HPV33 2.6 (1.2 to 4.0) 2.1 (1.3 to 2.9) 3.5 (2.5 to 4.5) 0.111
HPV45 4.2 (2.4 to 5.9) 3.6 (2.6 to 4.7) 4.2 (3.1 to 5.2) 0.837
HPV52 5.2 (3.2 to 7.1) 8.6 (7.0 to 10.2) 9.7 (8.1 to 11.2) 0.005
HPV58 3.0 (1.5 to 4.5) 3.2 (2.2 to 4.1) 3.4 (2.4 to 4.4) 0.605
*Defined as the additional HPV types included in the nonavalent vaccine (31, 33, 45, 52 and 58).
HPV, human papillomavirus.
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uncertainty, the reduction in the prevalence of
HPV31 postvaccination no longer reached statistical
signiﬁcance.
The percentage reductions between the postvaccina-
tion and prevaccination periods among the youngest two
age groups were very similar to the estimated vaccine
coverage. If all the reduction in prevalence was due to a
direct effect of vaccination, this would be consistent with
close to 100% vaccine effectiveness. Such high vaccine
effectiveness is unlikely given that women included in
this surveillance were largely vaccinated as part of the
catch-up programme, and almost certainly some of
those vaccinated would have had an existing HPV infec-
tion. These high reductions could be partly explained by
the fact that nationally published data that was used to
estimate vaccination coverage is based on reported data
on vaccination administration. A recent study of sero-
logical markers has suggested that these administration
data may be under-reporting HPV vaccinations among
women eligible for vaccination as part of the catch-up
programme (D Mesher, E Stanford, J White, et al. HPV
serology testing conﬁrms high HPV immunisation cover-
age in England. Submitted for publication 2015). This
would mean that the vaccination coverage we had esti-
mated for our surveillance population would have been
a slight under-estimate. This would be more consistent
with the relatively high overall reductions in HPV16/18
we observed although it is most likely that these are due
to a combination of both higher vaccination coverage
and some herd protection effect.
This surveillance makes use of a large sample of
residual specimens taken for chlamydia screening and
tested anonymously for HPV-DNA infection. Young
women attending for chlamydia screening have higher
risks of chlamydia, and therefore, probably for HPV
infection, than the general population. The reductions
in the HPV vaccine types (HPV16/18) observed here,
therefore, reassures that beneﬁts of HPV vaccination
have not been inequitably biased to lower risk
individuals.
The observation that the reductions in HPV16/18
were only seen in the age groups eligible for national
HPV vaccination, and reduced further in the later post-
vaccination period (ie, were proportionate to estimated
vaccination coverage), strongly suggests that the changes
seen are attributable to vaccination.
If increases in the other HR-HPV types were restricted
to the younger age groups, or were greater in the later
postvaccination period with higher vaccination coverage,
then this could raise suspicion of potential type replace-
ment. However, the increases seen in the non-vaccine
HPV types were seen in all age groups, including the
older unvaccinated women, which suggest that these
increases are unlikely to be due to type replacement,
and are more likely a result of limitations in our study.
First, comparison of HPV prevalence between the pre-
vaccination and postvaccination periods were adjusted
for age, venue type and chlamydia positivity (as a
marker of sexual behaviour). However, other changes in
the population characteristics (or sexual behaviour not
captured by chlamydia positivity) may have resulted in a
change in prevalence of the non-vaccine HR-HPV types.
If women in the postvaccination period were at a higher
risk of HPV infection then this could have underesti-
mated the potential effect of HPV vaccination on the
HPV vaccine types. Analyses restricted to women with at
least one HR-HPV type show larger declines for HPV31
and evidence of a reduction in HPV45 which would
support this hypothesis. Furthermore, these analyses
restricted to HR-HPV-positive specimens show little dif-
ference in relative prevalence of HPV52 or 58, which
strengthens our conclusion that these increases are
probably not due to type replacement. Second, there
Figure 1 Prevaccination and postvaccination prevalence of
human papillomavirus (HPV) types by age. Percentages in
square brackets represent estimated three-dose HPV
vaccination coverage for individuals aged 16–18, 19–21 and
22–24 years, respectively. HR, high risk.
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was a change in the assay used between the postvaccina-
tion and prevaccination periods, but no change in the
assay used throughout the postvaccination period;
hence, continued reductions in the vaccine HPV types
within the postvaccination period cannot be affected by
this. However, it was necessary to adjust ORs comparing
the prevaccination and postvaccination periods for the
different assays used. Finally, broad-spectrum assays, such
as those used in our study, can lack sensitivity to detect
individual HPV types at low copy number in the pres-
ence of other HPV types. Therefore, the decrease in
multiple HPV infections due to the reduction in HPV16
and 18 following vaccination could lead to an apparent,
artiﬁcial increase in the prevalence of certain non-
vaccine HPV types (ie, unmasking). Given that the
increases in certain HPV types were apparent between
the prevaccination and postvaccination periods, but
remained relatively stable within the postvaccination
period, this suggests that unmasking is not playing a
huge role in these increases. However, while adjustment
was made for the change in assay between the two
periods, to what extent increases in non-vaccine types
are due to temporal changes, changes in the population
undergoing chlamydia screening, or changes in the
detection accuracy of assays, is still somewhat unclear.
In England, the quadrivalent vaccine was introduced
to the national HPV immunisation programme from
2012 as part of routine vaccination of 12-year-old girls.
At the time this surveillance was conducted, the oldest
women vaccinated with the quadrivalent vaccine as part
of the national programme would have been 14 years
old, hence, too young to be included in this surveil-
lance (conducted among individual aged 16–24 years).
Therefore, all women included in this surveillance who
were vaccinated as part of the national immunisation
programme would have received the bivalent HPV
vaccine. We were unable to link these specimens to
individual HPV vaccination status, and coverage esti-
mates were derived from published data. This meant
that we considered population-level impact of HPV vac-
cination rather than direct calculation of vaccine effect-
iveness. Our ﬁndings of reductions in the prevalence of
the HPV vaccine types are consistent with surveillance
conducted in other countries, although changes in the
prevalence of non-vaccine HR-HPV types varied.27
Tabrizi et al14 showed a 77% reduction in the preva-
lence of HPV vaccine types among young women
attending for a Pap test in Australia. In the USA, reduc-
tions in the prevalence of HPV vaccine types were 56%
in individuals aged 14–19 years, despite a low self-
reported vaccination coverage (34% with one or more
doses). 17 In Sweden, surveillance also among women
attending for chlamydia screening found a reduction of
42% in HPV16 and 46% in HPV18 among females
aged 13–22 years, and also a slight increase in HPV52
and 56.19 In Scotland, where cervical screening is
offered from age 20 years, a 54% reduction in the
vaccine types has been shown in individuals aged
20 years, as well as a 48% reduction in the cross-
protection types HPV31, 33 and 45.18
Table 3 Prevalence and OR of HPV infection in the postvaccination period compared to prevaccination, by age group
Prevaccination:
n (%)
Postvaccination:
n (%) OR (95% CI)
Adjusted OR*
(95% CI)
16–18 years
(Estimated HPV16/18 vaccination coverage) (0%) (67.2%)
HPV16/18 with or without other HR types 184 (17.6%) 121 (6.1%) 0.3 (0.2 to 0.4) 0.3 (0.2 to 0.4)
HPV16/18 alone 80 (7.6%) 55 (2.8%) 0.3 (0.2 to 0.5) 0.5 (0.3 to 1.3)
Non-vaccine HR type(s) with or without HPV16/18 261 (24.9%) 672 (33.7%) 1.5 (1.3 to 1.8) 1.3 (1.0 to 1.7)
HPV31/33/45 88 (8.4%) 126 (6.3%) 0.7 (0.6 to 1.0) 0.9 (0.5 to 1.5)
HPV31/33/45/52/58 152 (14.5%) 323 (16.2%) 1.1 (0.9 to 1.4) 1.2 (0.9 to 1.7)
19–21 years
(Estimated HPV16/18 vaccination coverage) (0%) (30.7%)
HPV16/18 with or without other HR types 136 (16.9%) 322 (11.6%) 0.6 (0.5 to 0.8) 0.6 (0.5 to 0.9)
HPV16/18 alone 60 (7.5%) 153 (5.5%) 0.7 (0.5 to 1.0) 1.2 (0.6 to 4.5)
Non-vaccine HR type(s) with or without HPV16/18 216 (26.9%) 1098 (39.6%) 1.8 (1.5 to 2.1) 1.5 (1.1 to 2.0)
HPV31/33/45 67 (8.3%) 242 (8.7%) 1.1 (0.8 to 1.4) 1.3 (0.8 to 2.6)
HPV31/33/45/52/58 122 (15.2%) 575 (20.7%) 1.5 (1.2 to 1.8) 1.5 (1.1 to 2.2)
22–24 years
(Estimated HPV16/18 vaccination coverage) (0%) (0.6%)
HPV16/18 with or without other HR types 77 (15.3%) 416 (16.3%) 1.1 (0.8 to 1.4) 1.1 (0.8 to 1.7)
HPV16/18 alone 32 (6.4%) 219 (8.6%) 1.4 (0.9 to 2.0) 2.5 (1.2 to 329.2)
Non-vaccine HR type(s) with or without HPV16/18 133 (26.4%) 839 (32.9%) 1.4 (1.1 to 1.7) 1.2 (0.9 to 1.6)
HPV31/33/45 45 (8.9%) 231 (9.1%) 1.0 (0.7 to 1.4) 1.2 (0.7 to 2.5)
HPV31/33/45/52/58 84 (16.7%) 506 (19.8%) 1.2 (1.0 to 1.6) 1.3 (0.9 to 2.0)
*Adjusted for age, venue type, chlamydia positivity and change in HPV assay between prevaccination and postvaccination period.
HPV, human papillomavirus.
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We have analysed HPV type-speciﬁc prevalence among
almost 10,000 women over a period of 5 years. These
data provide clear evidence of a reduction in the HPV
vaccine types, and a suggestion of a reduction in HPV31,
a closely related HPV type, since the introduction of the
HPV immunisation programme in England. This will
both inform future decisions regarding HPV vaccination
in England and be of interest to other countries seeking
to monitor the impact of HPV vaccination.
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